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ABSTRACT
Sulfation is an important pathway of thyroid hormone metabolism
that facilitates the degradation of the hormone by the type I iodo-
thyronine deiodinase, but little is known about which human sulfo-
transferase isoenzymes are involved. We have investigated the sul-
fation of the prohormone T4, the active hormone T3, and the
metabolites rT3 and 3,39-diiodothyronine (3,39-T2) by human liver and
kidney cytosol as well as by recombinant human SULT1A1 and
SULT1A3, previously known as phenol-preferring and monoamine-
preferring phenol sulfotransferase, respectively. In all cases, the sub-
strate preference was 3,39-T2 .. rT3 . T3 . T4. The apparent Km
values of 3,39-T2 and T3 [at 50 mmol/L 39-phosphoadenosine-59-phos-
phosulfate (PAPS)] were 1.02 and 54.9 mmol/L for liver cytosol, 0.64
and 27.8 mmol/L for kidney cytosol, 0.14 and 29.1 mmol/L for
SULT1A1, and 33 and 112 mmol/L for SULT1A3, respectively. The
apparent Km of PAPS (at 0.1 mmol/L 3,39-T2) was 6.0 mmol/L for liver
cytosol, 9.0 mmol/L for kidney cytosol, 0.65 mmol/L for SULT1A1, and
2.7 mmol/L for SULT1A3. The sulfation of 3,39-T2 was inhibited by the
other iodothyronines in a concentration-dependent manner. The in-
hibition profiles of the 3,39-T2 sulfotransferase activities of liver and
kidney cytosol obtained by addition of 10 mmol/L of the various an-
alogs were better correlated with the inhibition profile of SULT1A1
than with that of SULT1A3. These results indicate similar substrate
specificities for iodothyronine sulfation by native human liver and
kidney sulfotransferases and recombinant SULT1A1 and SULT1A3.
Of the latter, SULT1A1 clearly shows the highest affinity for both
iodothyronines and PAPS, but it remains to be established whether
it is the prominent isoenzyme for sulfation of thyroid hormone in
human liver and kidney. (J Clin Endocrinol Metab 84: 1357–1364,
1999)
SULFATION is a detoxication reaction that increases thewater solubility of a variety of endogenous and exog-
enous lipophilic compounds, thus facilitating their excretion
in bile and/or urine (1–3). Sulfation is also an important
pathway for the metabolism of thyroid hormone, increasing
the hydrophilicity and the biliary excretion of the hormone.
However, the major purpose of sulfation of thyroid hormone
is to facilitate its degradation by the type I iodothyronine
deiodinase (D1) (4, 5). This selenoenzyme catalyzes the outer
ring deiodination (ORD) as well as the inner ring deiodina-
tion (IRD) of different iodothyronines, including the ORD of
the prohormone T4 to the active hormone T3 and the IRD of
T4 and T3 to the inactive metabolites rT3 and 3,39-diiodothy-
ronine (3,39-T2), respectively (6, 7). The preferred substrate
for D1 is rT3, which is converted by ORD to 3,39-T2 (6, 7).
An intriguing characteristic of D1 is that its deiodination
of a number of iodothyronines is accelerated by sulfation of
their phenolic hydroxyl group (4, 5). Thus, IRD of both T4
sulfate (T4S) and T3 sulfate (T3S) by rat D1 is 40–200 times
faster than deiodination of the nonsulfated substrates. In
contrast, ORD of T4 by rat D1 is completely blocked by
sulfation (4, 5). This is not a general phenomenon, as ORD of
rT3 by rat D1 is not affected by sulfation, whereas ORD of
3,39-T2 by rat D1 is accelerated about 50-fold by sulfation of
this compound (4, 5). Similar findings have been obtained
with human and dog D1 (8, 9). The facilitated deiodination
of sulfated iodothyronines is a unique property of D1. Nei-
ther the type II iodothyonine deiodinase (D2), which cata-
lyzes only ORD, e.g. T4 to T3 and rT3 to 3,39-T2, nor the type
III iodothyronine deiodinase (D3), which catalyzes only IRD,
e.g. T4 to rT3 and T3 to 3,39-T2, is capable of catalyzing the
deiodination of sulfated iodothyronines (10, 11).1
Serum concentrations of T4S, T3S, rT3S, and 3,39-T2S are
low in normal human subjects, but they are high in fetal and
cord blood, in patients with nonthyroidal illness, and in
patients treated with propylthiouracil or iopanoic acid, in-
hibitors of D1 (12–19). The serum T3S/T3 ratio is also in-
creased in hypothyroid patients (13). High serum T4S, T3S,
rT3S, and 3,39-T2S levels have also been detected in serum,
bile, allantoic fluid, and amniotic fluid of fetal sheep (19–22).
The high serum iodothyronine sulfate levels during nonthy-
roidal illness, hypothyroidism, and fetal development have
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been ascribed to a low peripheral D1 activity in these con-
ditions (4, 5, 11). These results are in accordance with ex-
perimental findings in rats showing marked increases in the
serum concentration and biliary excretion of iodothyronine
sulfates in animals with impaired hepatic and renal D1 ac-
tivities due to administration of D1 inhibitors or selenium
deficiency (23–27). These changes are not caused by an in-
creased sulfation of iodothyronines, but, rather, by a de-
creased clearance of the sulfated iodothyronines by D1 (24,
28). Thus, sulfation is a primary step leading to the irrevers-
ible degradation of T4 and T3 by D1. However, if D1 activity
is low, inactivation of thyroid hormone by sulfation is re-
versible due to expression of sulfatases in different tissues
and by intestinal bacteria (11, 29–31). It has been speculated
that especially in the fetus, T3S has an important function as
a reservoir from which active T3 may be released in a tissue-
specific and time-dependent manner (5, 11).
Sulfation of the hydroxyl group of a variety of substrates
is catalyzed by a family of homologous sulfotransferases
located in the cytoplasmic fraction of different tissues, such
as liver, kidney, intestine, and brain (1–3). All of these isoen-
zymes use 39-phosphoadenosine-59-phosphosulfate (PAPS)
as sulfate donor (1–3). On the basis of substrate specificity
and amino acid sequence homology, two sulfotransferase
families have been recognized in human tissues, i.e. phenol
sulfotransferases (including estrogen sulfotransferases) and
hydroxysteroid sulfotransferases (1–3). It is not known
which sulfotransferases are involved in the sulfation of io-
dothyronines in human tissues. Previous studies have sug-
gested a role for the enzymes termed phenol-preferring phe-
nol sulfotransferase (P-PST) and monoamine-preferring
phenol sulfotransferase (M-PST), in the sulfation of T3 in
human liver and intestine (32, 33). Recently, a large number
of human and rat sulfotransferases have been cloned and
characterized, including human SULT1A1 and SULT1A3,
which represent P-PST and M-PST, respectively (34–36), un-
der a new nomenclature system. Here we report the results
of a comparison of the kinetic profiles of the sulfation
of iodothyronines by human liver and kidney cytosol and





125I]T3 were obtained from Amersham (Ayles-
bury, UK); T4, T3, and PAPS from Sigma Chemical Co. (St. Louis, MO);
rT3, 3,5-T2, 3,39-T2, 39,59-T2, 3- and 39-iodothyronine (T1), and thyronine
(T0) from Henning (Berlin, Germany); and Sephadex LH-20 from Phar-
macia (Woerden, The Netherlands). 3,[39-125I]T2 and [39,59-
125I]rT3 were
prepared by radioiodination of 3-T1 and 3,39-T2, respectively, as previ-
ously described (37).
Normal adult human liver and kidney tissues were obtained at sur-
gery for liver and kidney tumors. Approval was obtained from the
medical ethical committee of Erasmus University Medical School and
Hospital. Tissue was homogenized in 0.25 mol/L sucrose, 10 mmol/L
HEPES (pH 7.0), and 1 mmol/L dithiothreitol, and cytosol was prepared
as previously described (8). SULT1A1 complementary DNA (cDNA)
cloned by Wilborn et al. (34) and SULT1A3 cDNA cloned by Ganguly et
al. (36) were provided by Dr. C. N. Falany (University of Alabama,
Birmingham, AL) and expressed in Salmonella typhimurium as previously
described (38). Human SULT1A3 cDNA was also cloned from human
platelets and expressed in V79 cells (35). Bacterial and V79 cell cytosols
were prepared for characterization of recombinant sulfotransferase ac-
tivities (35, 38). Protein was measured with the Bio-Rad protein assay
(Bio-Rad, Veenendaal, The Netherlands), using BSA as the standard.
Sulfotransferase assay
Iodothyronine sulfotransferase activities were analyzed by incuba-
tion of 0.1 mmol/L T4, T3, rT3, or 3,39-T2 and 100,000 cpm of the
125I-
labeled compound for 30 min at 37 C with the indicated amounts of liver
or kidney cytosol or recombinant sulfotransferase preparation in the
presence or absence (blank) of 50 mmol/L PAPS in 0.2 mL 0.1 mol/L
phosphate (pH 7.2) and 2 mmol/L ethylenediamine tetraacetate (39).
Similar results were obtained in the absence of ethylenediamine tet-
raacetate. The reactions were started by the addition of enzyme diluted
in ice-cold buffer and were stopped by the addition of 0.8 mL 0.1 mol/L
HCl. The mixtures were analyzed for sulfoconjugate formation by chro-
matography on Sephadex LH-20 minicolumns as previously described
(39). Sulfation in reaction mixtures with PAPS was corrected for back-
ground radioactivity detected in the corresponding Sephadex LH-20
fractions of the blanks. Incubations were carried out in triplicate, and the
coefficient of variation was less than 10%.
Results
Figure 1 shows the sulfation of 0.1 mmol/L T4, T3, rT3, and
3,39-T2 by human liver and kidney cytosol, SULT1A1, and
SULT1A3 in the presence of 50 mmol/L PAPS. All enzyme
preparations display a strong substrate preference for 3,39-T2,
which is sulfated approximately 2 orders of magnitude more
rapidly than T3 and rT3, whereas T4 is a poor substrate for
these human sulfotransferases.
Figure 2 presents the sulfation of 3,39-T2 by human liver
cytosol in the presence of PAPS as a function of incubation
time and cytosolic protein concentration. Under the condi-
tions used, 3,39-T2 sulfation was linear with incubation time
up to 45 min, when about 50% of the substrate was converted
(Fig. 2A). The subsequent decrease in sulfation rate was
probably due to depletion of substrate rather than depletion
of cofactor, because PAPS was added in large excess (50
mmol/L). Initially, 3,39-T2 sulfation showed a more than pro-
portional increase with the cytosolic protein concentration
(Fig. 2B). For instance, an increase in the cytosolic protein
FIG. 1. Sulfation of iodothyronines by human liver and kidney cy-
tosol, SULT1A1, and SULT1A3. Reaction conditions were 0.1 mmol/L
125I-labeled T4, T3, rT3, or 3,39-T2; 0.1 mg protein/mL; 50 mmol/L
PAPS; and 30-min incubation. Results are the means of triplicate
determinations from a representative experiment.
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concentration from 25 to 50 mg/mL resulted in a 3-fold in-
crease in 3,39-T2S formation. Further increases in protein
concentration resulted in roughly linear increases in 3,39-T2
sulfation until significant substrate depletion occurred. Sim-
ilar results were obtained when 3,39-T2 sulfation by human
kidney cytosol was analyzed as a function of the cytosolic
protein concentration (data not shown).
Figure 3 shows the sulfation of 3,39-T2 by human liver (A)
and kidney (B) cytosol as a function of the substrate con-
centration. In both tissues, saturation kinetics were observed
in the range of the 3,39-T2 concentrations tested, with max-
imum sulfation rates obtained at 3 mmol/L 3,39-T2. At higher
3,39-T2 concentrations, a decrease in the sulfation rate was
observed, suggesting substrate inhibition. The double recip-
rocal plots of sulfation rate vs. 3,39-T2 concentration were
linear, allowing the calculation of apparent Km values for
3,39-T2 and maximal velocity (Vmax) values. Table 1 presents
the kinetic parameters for 3,39-T2 sulfation by human liver
and kidney cytosol at 50 mmol/L PAPS determined in dif-
FIG. 2. Effects of incubation time (A) and protein concentration (B)
on the sulfation of 3,39-T2 by human liver cytosol. Reaction conditions
were 1 mmol/L 3,[39-125I]T2, 50 mg protein/mL (A), 50 mmol/L PAPS,
and 20-min incubation (B). Results are the means of triplicate de-
terminations from a representative experiment.
FIG. 3. Effects of substrate concentration on the sulfation of 3,39-T2
by human liver (A) or kidney cytosol (B). The insets show the double
reciprocal plot. Reaction conditions were 0.1–3 mmol/L 3,[39-125I]T2,
50 (A) or 100 (B) mg protein/mL, 50 mmol/L PAPS, and 60-min incu-
bation.
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ferent experiments. The mean apparent Km for 3,39-T2 was
1.02 mmol/L in liver and 0.64 mmol/L in kidney cytosol. The
data presented were obtained using three different kidney
samples and two different cytosol preparations from the
same liver, whereas very similar results were obtained with
59 other liver samples.2 Table 1 also gives the kinetic pa-
rameters for the sulfation of T3 determined under similar
conditions. Compared with 3,39-T2, apparent Km values for
T3 were approximately 50-fold higher, i.e. 54.9 mmol/L in
liver and 27.8 mmol/L kidney, whereas apparent Vmax values
were roughly 10-fold lower.
Figure 4 depicts the sulfation of 3,39-T2 by SULT1A1 (A)
and SULT1A3 (B) as a function of the substrate concentration.
Maximum sulfation rates were obtained at lower 3,39-T2 con-
centrations for SULT1A1 than for SULT1A3, with SULT1A1
showing clear substrate inhibition at 3,39-T2 levels above 1
mmol/L. From the linear double reciprocal plots, apparent
Km and Vmax values were calculated. As the enzymes ex-
pressed in Salmonella and V79 cells were tested as crude
cytosol, the maximum sulfation rates determined in these
experiments are not representative of the differences in kcat
values between the different isoenzymes. The kinetic param-
eters determined in different experiments are summarized in
Table 1, showing mean Km values of 0.14 and 33 mmol/L for
3,39-T2 sulfation by SULT1A1 and SULT1A3, respectively.
Apparent Km values were identical for SULT1A3 expressed
in either Salmonella or V79 cells. Again, T3 sulfation was
characterized by much higher apparent Km values, i.e. 29.1
mmol/L for SULT1A1 and 112 mmol/L for SULT1A3, and
lower apparent Vmax values compared with those for 3,39-T2
(Table 1).
Figure 5 shows the effects of increasing PAPS concentra-
tion on the sulfation of 0.1 mmol/L 3,39-T2 by human liver (A)
and kidney (B) cytosol. Sulfation approached maximum rates
at PAPS concentrations of 30 mmol/L or more. The double
reciprocal plots of these data were linear, from which Km and
Vmax values (at 0.1 mmol/L 3,39-T2) were calculated. Table 1
summarizes the results from different experiments. The
mean apparent Km value for PAPS was 6 mmol/L in liver and
9 mmol/L in kidney cytosol.
Figure 6 presents the sulfation of 0.1 mmol/L 3,39-T2 by
SULT1A1 (A) and SULT1A3 (B) as a function of the PAPS
concentration. The PAPS concentration required for maxi-
mum sulfation rates was lower for SULT1A1 than for
SULT1A3. The apparent Km values for PAPS (at 0.1 mmol/L
2 Gilissen, R. A. H. J., M. W. H. Coughtrie, E. Kaptein, and T. J. Visser,
unpublished work.
FIG. 4. Effects of substrate concentration on the sulfation of 3,39-T2
by SULT1A1 (A) and SULT1A3 (B). The insets show the double re-
ciprocal plot. Reaction conditions were 0.1–100 mmol/L 3,[39-125I]T2,
5 (A) or 100 (B) mg protein/mL, 50 mmol/L PAPS, and 30-min incu-
bation.
TABLE 1. Kinetic parameters of human iodothyronine
sulfotransferases
Enzyme source Km (mmol/L)
Vmax
(pmol/min z mg protein)
Variable substrate: 3,39-T2 (50 mmol/L PAPS)
Liver cytosol 1.02 6 0.11 337 6 88
Kidney cytosol 0.64 6 0.17 38.5 6 18.1
SULT1A1 (Salmonella) 0.12 6 0.05 465 6 184
SULT1A3 (Salmonella) 31.2 6 2.0 782 6 239
SULT1A3 (V79 cells) 34.7 6 6.1 2097 6 474
Variable substrate: T3 (50 mmol/L PAPS)
Liver cytosol 54.9 6 2.6 22.7 6 8.6
Kidney cytosol 27.8 6 2.6 2.7 6 0.1
SULT1A1 (Salmonella) 29.1 6 12.3 239 6 82
SULT1A3 (Salmonella) 112 6 23 158 6 94
Variable substrate: PAPS (0.1 mmol/L 3,39-T2)
Liver cytosol 6.00 6 0.25 21.4 6 3.4
Kidney cytosol 8.95 6 0.39 5.8 6 5.2
SULT1A1 (Salmonella) 0.65 6 0.12 177 6 34
SULT1A3 (V79 cells) 2.70 6 0.19 4.9 6 0.2
Data are presented as the mean 6 SD of two to five experiments.
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3,39-T2) calculated from the linear Lineweaver-Burk plots
were 0.65 and 2.7 mmol/L, respectively .
Figure 7 demonstrates the effects of increasing concentra-
tions (1–100 mmol/L) of unlabeled iodothyronines on the
sulfation of 3,[39-125I]T2 (1 mmol/L) by human liver cytosol.
T0 had no effect, whereas 3-T1 and 3,5-T2 produced only
10–20% inhibition at the highest concentration tested. All
other iodothyronines inhibited the sulfation of labeled 3,39-T2
dose dependently, with potencies decreasing in the order
3,39-T2 . rT3 . 39,59-T2 . 39-T1 . T3 ' T4.
Table 2 compares the effects of unlabeled iodothyronines
(10 mmol/L) on the sulfation of 3,[39-125I]T2 (1 mmol/L) by
human liver and kidney cytosol, SULT1A1, and SULT1A3. In
general, the magnitude of inhibition of the sulfotransferase
activities by the various iodothyronine analogs decreased in
the order SULT1A1 . liver ' kidney . SULT1A3. The in-
hibition profiles of the tissue sulfotransferase activities were
FIG. 5. Effects of cofactor concentration on the sulfation of 3,39-T2 by
human liver (A) or kidney (B) cytosol. The insets show the double
reciprocal plot. Reaction conditions were 0.1 mmol/L 3,[39-125I]T2, 50
(A) or 100 (B) mg protein/mL, 1–100 mmol/L PAPS, and 30-min in-
cubation.
FIG. 6. Effects of cofactor concentration on the sulfation of 3,39-T2 by
SULT1A1 (A) and SULT1A3 (B). The insets show the double recip-
rocal plot. Reaction conditions were 0.1 mmol/L 3,[39-125I]T2, 5 (A) or
100 (B) mg protein/mL, 1–100 mmol/L PAPS, and 30-min incubation.
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better correlated with the inhibition profile of SULT1A1 than
with that of SULT1A3 (liver vs. SULT1A1: r 5 0.936; P , 0.01;
liver vs. SULT1A3: r 5 0.793; P , 0.01; kidney vs. SULT1A1:
r 5 0.920; P , 0.01; kidney vs. SULT1A3: r 5 0.751; P , 0.01).
Discussion
Several human phenol sulfotransferases have been cloned
and characterized, including SULT1A1, SULT1A2,
SULT1A3, SULT1B1, and SULT1C1 (1–3, 34–36, 40–50).
SULT1A1 represents what has been known for some time as
the P-PST, whereas SULT1A3 was previously known as the
M-PST (1–3). The SULT1A isoenzymes are equally large pro-
teins consisting of 295 amino acids. A significant degree of
homology exists between the human SULT1A proteins, with
92% amino acid identity between SULT1A1 and SULT1A3
and an even greater degree of homology between SULT1A1
and SULT1A2, the genes of which are located close together
on chromosome 16 (2, 34–36, 40–46). Specifically, SULT1A1
and SULT1A2 differ in 11–15 amino acid positions, SULT1A1
and SULT1A3 differ in 20–23 amino acid positions, and
SULT1A2 and SULT1A3 differ in 30–31 amino acid positions.
Different allelic variants have been identified for SULT1A1
and SULT1A2 but to date not for SULT1A3 (2, 34–36, 40–46).
Sulfation of T3 by P-PST and M-PST purified from human
liver and intestine has been reported previously (32, 33), but
it remains to be determined which SULT1A isoenzyme is
most important for thyroid hormone sulfation in human liver
and other tissues. In addition to the members of the SULT1A
family, two other human phenol sulfotransferases, SULT1B1
(49, 50) and SULT1C1 (47, 48), have been cloned recently.
Whereas it is unknown whether isoenzymes homologous to
SULT1A2 and SULT1A3 exist in rats, the rat homologs of
human SULT1A1, SULT1B1, and SULT1C1 have been cloned
and characterized regarding their activity toward iodothy-
ronines (51–53). These studies have demonstrated that both
rat SULT1B1 and SULT1C1 catalyze the sulfation of different
iodothyronines, in particular 3,39-T2, whereas rat SULT1A1
is completely inactive. Human SULT1B1 has recently also
been shown to have sulfotransferase activity toward iodo-
thyronines (50), but sulfation of iodothyronines by human
SULT1C1 has not yet been reported.
We demonstrate that both human SULT1A1 and SULT1A3
are capable of catalyzing the sulfation of iodothyronines.
This is not surprising, as the sulfation of T3 by P-PST and
M-PST purified from human liver and intestine has been
reported previously (32, 33). We have also recently demon-
strated effective sulfation of iodothyronines by human
SULT1A2.3 It appears that small differences in amino acid
sequence can effect large differences in sulfotransferase ac-
tivity. The high activity of human SULT1A1 in contrast to the
complete lack of iodothyronine sulfotransferase activity of
rat SULT1A1 is remarkable, considering the high degree of
amino acid sequence identity (80%) between these ortholo-
gous proteins (2, 51). Likewise, the smaller (8%) difference in
amino acid sequence between human SULT1A1 and
SULT1A3 (34–36, 46) is associated with a more than 200-fold
difference in the Km value for 3,39-T2, a 4-fold difference in
the Km value for T3, and a 4-fold difference in the Km value
for PAPS. It should be noted that the apparent Km value of
3,39-T2 for SULT1A1 presented here is about 10-fold lower
than that mentioned previously (53), which may be due to
partial inactivation through oxidation (54) of the enzyme
preparation used previously.
The main purpose for comparing the substrate specificities
and kinetic parameters of native iodothyronine sulfotrans-
ferase activities in human liver and kidney with these prop-
erties of recombinant sulfotransferases is to try to identify the
isoenzymes that contribute most to the sulfation of thyroid
hormone in these tissues. The iodothyronine sulfotransferase
activities of human liver and kidney cytosol are character-
ized by similar apparent Km values for both 3,39-T2 and PAPS
as well as similar substrate specificities, suggesting the in-
volvement of similar isoenzymes. The substrate specificities
of the hepatic and renal sulfotransferase activities showed a
3 Kester, M. H. A., M. W. H. Coughtrie, H. Glatt, and T. J. Visser,
unpublished work.
FIG. 7. Effects of 1–100 mmol/L unlabeled iodothyronines on the sul-
fation of 3,[39-125I]T2 by human liver cytosol. Reaction conditions were
1 mmol/L 3,[39-125I]T2, 50 mg protein/mL, 50 mmol/L PAPS, and 30-min
incubation. Results are the means of triplicate determinations from
a representative experiment.




Liver Kidney SULT1A1 SULT1A3
T4 17 6 3 7 6 5 32 6 7 0 6 1
T3 4 6 2 3 6 4 24 6 4 1 6 2
rT3 43 6 4 42 6 10 86 6 1 1 6 1
39,59-T2 47 6 7 41 6 14 86 6 2 6 6 1
3,39-T2 87 6 2 88 6 2 95 6 1 19 6 2
3,5-T2 5 6 7 22 6 2 5 6 2 21 6 1
39-T1 71 6 12 61 6 18 99 6 1 38 6 2
3-T1 5 6 10 1 6 1 3 6 2 21 6 1
T0 21 6 2 0 6 1 22 6 6 22 6 1
3,[39-125I]T2 (1 mmol/L) was incubated for 30 min at 37 C with
appropriate amounts of enzyme protein in the absence or presence of
10 mmol/L unlabeled iodothyronine. The percent inhibition is calcu-
lated from the 3,[39-125I]T2 sulfation rate in the presence vs. that in
the absence of analog. Data are presented as the mean 6 SD of three
to six experiments using three liver and three kidney samples.
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better correlation with SULT1A1 than with SULT1A3, sug-
gesting that SULT1A1 is a prominent iodothyronine sulfo-
transferase in human liver and kidney. However, the differ-
ent iodothyronines showed a lower apparent affinity for the
native sulfotransferases than for recombinant SULT1A1,
which may be due to the presence of iodothyronine-binding
proteins in the tissues. Sulfation of thyroid hormone in hu-
man liver and kidney (and possibly other tissues) involves
contributions of at least SULT1A1, SULT1A2, SULT1A3, and
SULT1B1 and perhaps also SULT1C1. The complexity is fur-
ther increased by the polymorphic variation in these isoen-
zymes (2, 55) and their tissue-specific expression (56). In
addition, it has been demonstrated that functional rat phenol
sulfotransferases may consist of either two identical (ho-
modimer) or two different subunits (heterodimer) (57). Our
findings of a more than linear increase in iodothyronine
sulfotransferase activity with an increase in hepatic or renal
cytosolic protein concentration may reflect this requirement
for protein dimerization.
The native and recombinant sulfotransferases tested in this
study show a marked preference for 3,39-T2 as the substrate.
Both SULT1A1 and SULT1A3 are much less efficient in cat-
alyzing the sulfation of T3, which does not imply that these
isoenzymes are not important for T3 sulfation in vivo. This is
supported by the significant sulfation of T3 in both human
liver and kidney cytosol. Sulfation of T4 is almost undetect-
able, not only with recombinant SULT1A1 and SULT1A3 but
also in human liver and kidney. Nevertheless, high serum
T4S levels have been detected in human newborns (14, 15),
suggesting sulfation of T4 by other isoenzymes.
In conclusion, we have identified SULT1A1 and SULT1A3
as low Km and high Km human iodothyronine sulfotrans-
ferases, respectively, and obtained evidence that the sulfa-
tion of iodothyronines in human liver and kidney is cata-
lyzed by similar enzymes. Further investigations are
required to determine the possible importance of other isoen-
zymes, such as SULT1A2, SULT1B1, and SULT1C1, and of
polymorphic variations in the different sulfotransferases for
the sulfation of thyroid hormone in human tissues. This
information is essential for investigation of the regulation of
this important pathway of thyroid hormone metabolism un-
der (patho)physiological conditions, in particular during fe-
tal development.
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